 |
| David D. Ho, MD |
|
From random yet serendiptious web browsing (03/07):
Dr. Ho serves on the HIV Advisory Board of Achillion Pharmaceuticals, Inc., alongside other HIV luminaries Dr. John Mellors, Dr. Doug Richman, Dr. Robert 'Chip' Schooley and Dr. Richard Whitley. (Mellors reports owning Achillion stock options among his DHHS treatment guidelines panel disclosures but does not indicate his leadership position with the company. Dr. Schooley reports both in that same disclosure, but does not mention any relationship with Achillion in his IAS-USA disclosures. Dr. Richman does.)
2005 conflict of interest/competing interest disclosures for David D. Ho
GlaxoSmithKline: Chair of Drug Discovery Grants panel, 2001-05 (abruptly disbanded 07/05) ViroLogic (aka Monogram Biosciences): HIV Advisory Board, stock options Boehringer Ingelheim: Speaking honoraria Gilead Sciences: Speaking honoraria Merck: Speaking honoraria Abbott: Speaking honoraria
From The Lancet Ho has been a paid adviser to ViroLogic (renamed Monogram Biosciences in 2006) since its inception in 1995. Also serving with him on the Board are Dr. Doug Richman and Dr. Robert 'Chip' Schooley.
Source: Lancet 2005 vol 365; March 19, 2005: pp 1031-38.
|
|